City of Hope Researchers Present Advances in Targeted Therapies, Microbiome Science and Blood Cancers at ASCO 2026
New findings in kidney, liver and prostate cancers reflect the shift toward more personalized, biology-driven treatment.
Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, will present new findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, where the cancer center will showcase 49 abstracts spanning solid tumors and blood cancers.
This year’s research, to be presented in Chicago from May 29 to June 2, reflects growing efforts to tailor cancer treatment based on tumor biology, prior therapies and patient-specific factors that influence response.
“Cancer care is entering a new phase where understanding the biology of each patient’s disease is just as important as the treatment itself,” said Marcel van den Brink, M.D., Ph.D., City of Hope chief physician executive. “The research we are presenting at ASCO demonstrates how precision medicine is becoming a reality across cancer types, and how we can use that insight to deliver smarter therapies, improve outcomes and move the field forward.”
